157 related articles for article (PubMed ID: 32412910)
1. NAC1 attenuates BCL6 negative autoregulation and functions as a BCL6 coactivator of FOXQ1 transcription in cancer cells.
Gao M; Herlinger AL; Wu R; Wang TL; Shih IM; Kong B; Rangel LBA; Yang JM
Aging (Albany NY); 2020 May; 12(10):9275-9291. PubMed ID: 32412910
[TBL] [Abstract][Full Text] [Related]
2. Identification of the NAC1-regulated genes in ovarian cancer.
Gao M; Wu RC; Herlinger AL; Yap K; Kim JW; Wang TL; Shih IeM
Am J Pathol; 2014 Jan; 184(1):133-40. PubMed ID: 24200849
[TBL] [Abstract][Full Text] [Related]
3. Nucleus Accumbens 1, a Pox virus and Zinc finger/Bric-a-brac Tramtrack Broad protein binds to TAR DNA-binding protein 43 and has a potential role in Amyotrophic Lateral Sclerosis.
Scofield MD; Korutla L; Jackson TG; Kalivas PW; Mackler SA
Neuroscience; 2012 Dec; 227():44-54. PubMed ID: 23022214
[TBL] [Abstract][Full Text] [Related]
4. NAC1, a POZ/BTB protein that functions as a corepressor.
Korutla L; Wang P; Jackson TG; Mackler SA
Neurochem Int; 2009; 54(3-4):245-52. PubMed ID: 19121354
[TBL] [Abstract][Full Text] [Related]
5. Dysfunction of nucleus accumbens-1 activates cellular senescence and inhibits tumor cell proliferation and oncogenesis.
Zhang Y; Cheng Y; Ren X; Hori T; Huber-Keener KJ; Zhang L; Yap KL; Liu D; Shantz L; Qin ZH; Zhang S; Wang J; Wang HG; Shih IeM; Yang JM
Cancer Res; 2012 Aug; 72(16):4262-75. PubMed ID: 22665267
[TBL] [Abstract][Full Text] [Related]
6. Structures of heterodimeric POZ domains of Miz1/BCL6 and Miz1/NAC1.
Stead MA; Wright SC
Acta Crystallogr F Struct Biol Commun; 2014 Dec; 70(Pt 12):1591-6. PubMed ID: 25484205
[TBL] [Abstract][Full Text] [Related]
7. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein.
Dhordain P; Albagli O; Lin RJ; Ansieau S; Quief S; Leutz A; Kerckaert JP; Evans RM; Leprince D
Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10762-7. PubMed ID: 9380707
[TBL] [Abstract][Full Text] [Related]
8. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.
Parekh S; Polo JM; Shaknovich R; Juszczynski P; Lev P; Ranuncolo SM; Yin Y; Klein U; Cattoretti G; Dalla Favera R; Shipp MA; Melnick A
Blood; 2007 Sep; 110(6):2067-74. PubMed ID: 17545502
[TBL] [Abstract][Full Text] [Related]
9. NAC1, a cocaine-regulated POZ/BTB protein interacts with CoREST.
Korutla L; Degnan R; Wang P; Mackler SA
J Neurochem; 2007 May; 101(3):611-8. PubMed ID: 17254023
[TBL] [Abstract][Full Text] [Related]
10. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response.
Zhang Y; Cheng Y; Ren X; Zhang L; Yap KL; Wu H; Patel R; Liu D; Qin ZH; Shih IM; Yang JM
Oncogene; 2012 Feb; 31(8):1055-64. PubMed ID: 21743489
[TBL] [Abstract][Full Text] [Related]
11. Nac1 interacts with the POZ-domain transcription factor, Miz1.
Stead MA; Wright SC
Biosci Rep; 2014 Jun; 34(3):. PubMed ID: 24702277
[TBL] [Abstract][Full Text] [Related]
12. NAC-1, a potential stem cell pluripotency factor, contributes to paclitaxel resistance in ovarian cancer through inactivating Gadd45 pathway.
Jinawath N; Vasoontara C; Yap KL; Thiaville MM; Nakayama K; Wang TL; Shih IM
Oncogene; 2009 May; 28(18):1941-8. PubMed ID: 19305429
[TBL] [Abstract][Full Text] [Related]
13. Analysis of BCL6-interacting proteins by tandem mass spectrometry.
Miles RR; Crockett DK; Lim MS; Elenitoba-Johnson KS
Mol Cell Proteomics; 2005 Dec; 4(12):1898-909. PubMed ID: 16147992
[TBL] [Abstract][Full Text] [Related]
14. Protein complex formation and intranuclear dynamics of NAC1 in cancer cells.
Nakayama N; Kato H; Sakashita G; Nariai Y; Nakayama K; Kyo S; Urano T
Arch Biochem Biophys; 2016 Sep; 606():10-5. PubMed ID: 27424155
[TBL] [Abstract][Full Text] [Related]
15. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.
Walker SR; Nelson EA; Frank DA
Oncogene; 2007 Jan; 26(2):224-33. PubMed ID: 16819511
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K
Br J Cancer; 2012 Jul; 107(2):300-7. PubMed ID: 22653145
[TBL] [Abstract][Full Text] [Related]
17. Multi-SUMOylation of NAC1 is essential for the growth of prostate cancer cells.
Wen D; Hu M; Guo W; Wu J; Wu Y
Biochem Biophys Res Commun; 2023 Jan; 641():148-154. PubMed ID: 36527749
[TBL] [Abstract][Full Text] [Related]
18. Cell cycle-dependent alteration in NAC1 nuclear body dynamics and morphology.
Wu PH; Hung SH; Ren T; Shih IeM; Tseng Y
Phys Biol; 2011 Feb; 8(1):015005. PubMed ID: 21301057
[TBL] [Abstract][Full Text] [Related]
19. The LAZ3/BCL6 oncogene encodes a sequence-specific transcriptional inhibitor: a novel function for the BTB/POZ domain as an autonomous repressing domain.
Deweindt C; Albagli O; Bernardin F; Dhordain P; Quief S; Lantoine D; Kerckaert JP; Leprince D
Cell Growth Differ; 1995 Dec; 6(12):1495-503. PubMed ID: 9019154
[TBL] [Abstract][Full Text] [Related]
20. Biological role and prognostic significance of NAC1 in ovarian cancer.
Nakayama K; Rahman MT; Rahman M; Yeasmin S; Ishikawa M; Katagiri A; Iida K; Nakayama N; Miyazaki K
Gynecol Oncol; 2010 Dec; 119(3):469-78. PubMed ID: 20869761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
